TRZ
peptideevidence: emerging · v1Description
Tirz is a dual GLP-1 and GIP receptor agonist studied in glucose-regulation and metabolic research. Lyophilized powder. Reconstitute with bacteriostatic water for in-vitro research applications. Store at -20°C. Certificate of Analysis attached to this listing.
Mechanism summary
• Demonstrated up to 22.5% body weight reduction in clinical trials • Once-weekly subcutaneous injection for improved adherence • Significant HbA1c reduction (up to 2.58% in SURPASS trials) Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Type 2 diabetes (Mounjaro) and chronic weight management (Zepbound) [Source: Peptide Protocol Wiki]
How it works
Tirzepatide is a 39-amino-acid synthetic peptide with a fatty-acid attachment. The fatty acid is what lets it bind to blood proteins and stay in circulation long enough for once-weekly dosing — its half-life is roughly 5 days. Once in circulation, it activates two receptors that the gut normally talks to after a meal: GIP and GLP-1.
Tirzepatide activates GIP (glucose-dependent insulinotropic polypeptide) receptors at full strength, comparable to natural GIP. This helps the pancreas release insulin in response to food, improves how the body processes fat, and sends appetite-reducing signals to brain regions that GLP-1-only drugs do not reach.
Tirzepatide activates GLP-1 (glucagon-like peptide-1) receptors at about one-fifth the potency of natural GLP-1. This slows gastric emptying (so meals feel filling for longer), helps the pancreas tune insulin release, and suppresses appetite through brain signaling.
Adding GIP activation is what separates tirzepatide from semaglutide. In the head-to-head SURMOUNT-5 trial (NEJM, 2025), tirzepatide produced −20.2% body weight loss vs −13.7% for semaglutide at 72 weeks, with similar side-effect profiles. The dual approach also improved insulin sensitivity beyond what GLP-1 monotherapy delivered in SURPASS-2. [Source: Peptide Dosing Protocols]
In plain language
Tirzepatide is a synthetic peptide that helps control blood sugar and reduce appetite by activating two hormones, GIP and GLP-1, which work together to improve insulin release and slow digestion.
Reference details
Route(s)
—
Tags
—
Active
yes
Product details · TL2TZ-50
Price
$199.99
Stock
low stock
Mol. weight
4813.5 g/mol
Formula
C225H348N48O68
Purity
≥ 99%
CAS #
2023788-19-2
COA: View certificate (batch TET-4800-A) →
Teton Labs product catalog · research-use compound data.
💉 Dosing — 2 references (verbatim from source · not a recommendation)
Dose
2.5 mg starting dose, escalating to 5-15 mg maintenance
Route
subcutaneous or oral
Frequency
Once weekly
Duration
Ongoing (chronic therapy)
Source: Peptide Protocol Wiki (peptideprotocolwiki.com) (publication)Source-backedProvider-reviewed
Dose
Standard: 5 mg once weekly · Low: 2.5 mg once weekly · High: 15 mg once weekly
Route
Subcutaneous injection
Frequency
once weekly
Cycle
Cycle length Planning note 4 weeks (Phase 1, 2.
Reconstitution
2.0 mL BAC water for a 40 mg vial
Source: Peptide Dosing Protocols (peptidedosingprotocols.com) (publication)Source-backedProvider-reviewed
Safety, contraindications & monitoring
Contraindications — who should avoid
- Do not use it without a qualified prescriber if you have a personal or family history of medullary thyroid carcinoma or MEN 2.
Safety & side effects
- Tirzepatide carries a boxed warning for thyroid C-cell tumors.
Monitoring & bloodwork
- CBC at baseline and week 4
Clinical evidence
- ~22.5% weight loss at 72 weeks in SURMOUNT-1. · Jastreboff et al., NEJM 2022
Source-backedProvider-reviewedApproved findings drawn from your sources — decision support, not medical advice.
Provider-only reference. This page does not constitute medical advice, a recommendation, or dosing guidance.